Optiver Holding
SKYE icon

Optiver Holding’s Skye Bioscience SKYE Stock Holding History

Optiver Holding’s Portfolio SKYE Stock Details SKYE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12 Hold
20
– – ﹤0.01% 2277
2025
Q4 		$15 Hold
20
– – ﹤0.01% 2420
2025
Q3 		$79 Buy
+20
New +$76 ﹤0.01% 2605

Other funds holding SKYE

5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PIM
Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Optiver Holding's SKYE Position: Q1 2026 in Review

Optiver Holding held its Skye Bioscience (SKYE) position steady in Q1 2026 at 20 shares worth $12. The position accounts for ﹤0.01% of the portfolio, ranked #2277.

Optiver Holding first reported a position in SKYE in Q3 2025 and has held it in 3 quarters since. The position peaked at $79 in Q3 2025. 39 funds tracked by Wall St. Rank hold SKYE as of Q1 2026.

  • Optiver Holding held 20 shares of Skye Bioscience worth $12 as of Q1 2026.
  • Optiver Holding left its Skye Bioscience share count unchanged in Q1 2026.
  • Skye Bioscience made up ﹤0.01% of Optiver Holding's portfolio in Q1 2026, its #2277 holding.
  • Optiver Holding first reported a position in Skye Bioscience in Q3 2025 and has held it in 3 quarters since.
  • Optiver Holding's Skye Bioscience position peaked at $79 in Q3 2025.
  • 39 funds tracked by Wall St. Rank held Skye Bioscience as of Q1 2026.

Based on Optiver Holding's 13F filing for Q1 2026, filed 15 May 2026.